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ABSTRACT
STIMULANT USE, ASSOCIATED PSYCHOPATHOLOGY, AND
EATING DISORDERED SYMPTOMATOLOGY
by Tiffany Ann Hopkins
December 2013
The current study developed profiles of eating disorder, personality, and other
psychopathological symptoms related to the use of central nervous system stimulants
versus other types of drug use. Participants included 124 women in residential treatment
for substance use with and without comorbid eating disorders. Symptomatology was
measured by the Eating Disorders lnventory-3 (EDI-3), Millon Multiaxial Inventory-III
(MCMI-111), and Personality Assessment Inventory (PAl). The current study utilized a
series of six multivariate analyses of variance (MANOVAs) and discriminant analyses to
determine patterns of psychopathology separating stimulant use from other drug use.
Results indicated that women who used stimulants were primarily separated from women
who used other drugs by scales measuring borderline personality pathology, and to a
lesser extent, antisocial personality pathology. Stimulant users were also separated from
other drug users by scales measuring diagnostic or associated features of borderline
personality disorder (e.g., emotion dysregulation, suicide ideation, paranoia, aggression,
drug use, and thought disturbance) and mood disturbance. Finally, stimulant users were
differentiated from other drug users by a scale measuring extreme dieting and longing for
thinness. Implications for treatment and future research are discussed.

11

ACKNOWLEDGMENTS
This thesis would not have been possible without the support and guidance of my
committee chair and major professor, Dr. Bradley A. Green. His patience, flexibility, and
enthusiasm throughout the completion of this study were invaluable. Special thanks are
also given to Dr. Cathy Reto and The Women's Center at Pine Grove Behavioral Health
& Addiction Services, for their time, generosity, and thoughtful contributions to this

project. Additionally, I would like to thank my committee members, Dr. Michael Anestis
and Dr. Richard Mohn, for their valuable input and advice. Lastly, I would like to thank
my family and friends for their continued support and encouragement throughout the
completion of this project.

lll

TABLE OF CONTENTS
ABSTRACT ... ............. ...... ........... ... .. ...... ..................... . ....... . .... . .. .. ...... ii
ACKNOWLEDGMENTS .... ........ ... ... .. .... ...... .... .. ..... .......................... ..... iii
LIST OF TABLES .................................. ... ...... .. ... .... . ...... . ....... . ...... . ....... v
CHAPTER
I.

INTRODUCTION ............. . ........ ... ...... ... .... .. ........ ... .... . ......... . .... 1
Substance Use Disorders and Eating Disorders
Substance Use and Associated Psychopathology
Eating Disorders and Associated Psychopathology
The Present Study

II.

METHODOLOGY .......................................... . .... . ................ .. 22
Subjects
Procedure
Instruments
Statistical Plan

III.

ANALYSES AND RESULTS ...... ... .............................................. 33
Preliminary Analyses
Results, EDI-3
Results, PAI
Results, MCMI-III

IV.

SUMMARY ....................... .... .... ................ . .... . ......... . ...... .. ..... 48
Discussion
Implications for Treatment
Limitations of the Current Study
Future Directions

APPENDIX ..................................................................................................................... 58
REFERENCES ................................................................................................................ 60

IV

LIST OF TABLES
Table
1. Summary of Reported Findings .. ........ ................. .... .. .... ...... .. .... ...... ....... 20
2. Results from Levene's Test for Equality of Variance; All Scales . .. ...... .. ... ... ... ... 34
3. A Priori Univariate Analyses, EDI-3 .. .. ...... ..... .. .. .. . .......... ....... ......... ........ 36
4. A Priori Discriminant Analysis Results, EDI-3 ...... ................ .... ... ................ 37
5. A Priori Univariate Analyses, PAl ....... ........ .......... . ................. .. ... ..... ... .. 39
6. A Priori Discriminant Analysis Results, PAI ....... .. .... .. ......... .. .. .. .. ................ 40
7. Heuristic Univariate Analyses, PAl .. . ... .... ................................. .. ... ......... 41
8. Heuristic Discriminant Analysis Results, PAI ......... .... ...... .... .. ........ . ........... 42
9. A Priori Univariate Analyses, MCMI-III ....... ... ............ .. ... ...... . .... .... ... ..... 43
10. A Priori Discriminant Analysis Results, MCMI-III ... ..... .... . .................... .. ... 44
11. Unplanned Univariate Analyses, MCMI-III ......... ... ...... .... .. ...... ... . ..... ........ 45
12. Heuristic Discriminant Analysis Results, MCMI-III ... .......... .... ..................... 46

v

1

CHAPTER I
INTRODUCTION
Stimulant use is increasingly prevalent in recent decades. Women now equal men
in stimulant use and demonstrate unique susceptibility to stimulant addiction due to
hormonal interactions with stimulants (Greenfield, Back, Lawson, & Brady, 2010). The
use of stimulants is of particular concern for those with eating disordered symptoms, as
stimulant use is associated with decreased appetite, improved mood, and weight loss
(National Center of Addiction and Substance Abuse (CASA) at Columbia University,
2003). Comorbidity between substance use disorders and eating disorders is associated
with greater psychopathology and poorer prognosis than the individual diagnosis of either
disorder (see review: Pearlstein, 2002). The current study assessed differences in
personality, psychopathology, and eating disordered symptoms associated with the use of
stimulants versus other types of drugs.
The background for the present study will be established by first reviewing the
literature relating substance use disorders to eating disorders, then the literature linking
substance use disorders to other forms of psychopathology, then the literature relating
eating disorders to other forms of psychopathology. The integration of these three lines of
research provide the basis for the present work. The current study addresses a void in the
literature by examining clinical presentation based on type of substance use. Differences
in clinical presentation will highlight the need to establish specific treatment modalities
based on substance type, eating disorder symptomatology, and associated
psychopathology.
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Substance Use Disorders and Eating Disorders
Substance use disorders encompass both substance dependence and substance
abuse. The Diagnostic and Statistical Manual (DSM-IV-TR; American Psychiatric
Association (APA), 2000) defines the central elements of substance dependence as "a
cluster of cognitive, behavioral, and physiological symptoms indicating that the
individual continues use of the substance despite significant substance-related problems"
(APA, 2000, p. 192). Individuals with substance dependence often manifest tolerance and
withdrawal symptoms, desire to decrease substance use, and persist using the substance
regardless of the negative physical and psychological effects 'caused by the substance.
Substance abuse is described in the DSM-IV-TR as "a maladaptive pattern of substance
use manifested by recurrent and significant adverse consequences related to the repeated
use of substances" (APA, 2000, p. 198). Specifically, consequences may include
difficulty fulfilling major role obligations, interpersonal issues, bodily harm, and legal
ramifications.
Substance use disorders are categorized on the basis of substance type (APA,
2000). Central nervous system stimulants (hereafter: stimulants) include such drugs as
nicotine, caffeine, methylphenidate (e.g. Ritalin), amphetamines (e.g., Adderall),
methamphetamines (e.g. speed), and cocaine. Stimulants act on the mesocorticolimbic
pathway of the brain, also known as the reward pathway, by increasing dopamine levels
in the nucleus accumbens (Badiani,Belin, Epstein, Calu, & Shaham, 2011). Stimulant
use is associated with a number of physiological responses, such as diminished appetite,
hyper-alertness, improved concentration, and elevated mood; in greater amounts, it can
result in such symptoms as rapid heart rate and breathing, sweating, tremor, and high
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blood pressure (National Center of Addiction and Substance Abuse (CASA) at Columbia
University, 2003; Weaver & Schnoll, 1999). Additionally, large, acute doses of
amphetamine have been linked to aggression and transient psychotic symptoms,
including paranoia, delusions, and hallucinations; the chronic use of amphetamines may
result in persistent symptoms of psychosis and paranoia (reviews: Dawe, Davis,
Lapworth, & McKetin, 2009; Shoptaw, Kao, & Ling, 2009).
The DSM-IV-TR (APA, 2000) outlines three eating disorder types and two eating
disorder subtypes. Anorexia nervosa (AN) is diagnosed when "the individual refuses to
maintain a minimally normal body weight, is intensely afraid of gaining weight, and
exhibits a significant disturbance in the perception of the shape or size of his or her body"
(APA, 2000, p. 583). Furthermore, the AN diagnosis can be subtyped into a restricting
type (ANr) if the focus is on fasting and dieting, and a binge-eating and purging subtype
(ANbp) when there is a cycle ofbinge-eating and purging (e.g., vomiting, laxative
misuse). Criteria of bulimia nervosa (BN) include "binge eating and inappropriate
compensatory methods to prevent weight gain" and "self-evaluation [which is] unduly
influenced by body shape and weight" (APA, 2000, p. 589). Finally, EDNOS captures a
wide variety of disordered eating, including binge-eating without purging (i.e., binge
eating disorder) and subclinical AN or BN (APA, 2000, p. 594). Several studies
examined associations between specific eating disorder types/behaviors and substance
use.
Stimulant use and eating disorder symptomatology have numerous overlapping
consequences, which may be more severe when the disorders occur comorbidly.
Specifically, these two disorders consistently demonstrate some of the highest mortality
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rates associated with psychological disorders (Arendt, Munk-J0rgensen, Sher, & Jensen,
2011 ; Crow et al., 2009), with the substance use-eating disorder comorbidity resulting in
higher mortality rates than any other psychiatric comorbidity. Mortality is particularly
related to substance misuse or overdose and suicide (Franko et al., 2005; Rosling, Sparen,
Norring, & von Knorring, 2011). Additionally, both substance use and eating disorder
symptomatology are associated with harmful and often irreversible health effects (Harrop
& Marlatt, 2010; Greenfield, Gordon, Cohen & Trucco, 2010; Sansone & Sansone,

1994), pre- and posttreament impairments in quality oflife (Hay & Mond, 2005, Tracy et
al., 2012), increased social costs (e.g., treatment, job productivity) relative to normative
populations (Meara & Frank, 2005), and increased health-related economic burden
(Mitchell et al., 2009; Simon, Schmidt, & Pilling (2005). Additionally, there is an
indication that those with particular combinations of comorbid diagnoses may have better
outcomes associated with specific types of treatments. For example, Franko et al. (2005)
found that recovery of alcohol use disorder with comorbid AN was best predicted by
group therapy and hospitalization, whereas recovery from comorbid alcohol use disorder
and BN was best predicted by individual therapy and exercise. Thus, an examination of
these patterns of comorbidities may result in improved treatment outcomes and
diminished consequences.
The literature is replete with studies examining the individual relationship
between substance use disorders and eating disorders. Wiederman and Pryor (1996)
described prevalence rates for substance use in the eating disorder population as ranging
from 17% to 46% depending on the type and subtype of eating disorder. In a review of
the literature, Holderness, Brooks-Gunn, and Warren (1994) found that of those
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diagnosed with BN, up to 48.6% of individuals were also diagnosed with alcohol abuse
or dependence, and up to 55% were diagnosed with any drug abuse or dependence.
Similarly, across studies, they found that of individuals diagnosed with AN restricting
type, up to 34% were diagnosed with alcohol abuse or dependence and up to 19% used
illegal drugs. Finally, they reported that of individuals who were diagnosed with a
combination of anorexic and bulimic symptoms, up to 45% also were diagnosed with
alcohol abuse or dependence and up to 40% reported using street drugs. There is a clear
and substantial relationship between substance use disorders and eating disorders.
Although individuals with eating disorders may use a wide range of substances,
there appears to be a unique relationship between stimulant use and eating disordered
symptomatology. The National Center of Addiction and Substance Abuse (CASA) at
Columbia University (2003) found that smoking and eating disorder symptomatology
were closely linked, in that nicotine suppresses appetite and provides an oral replacement
to eating. They stated that women who smoke reference potential weight gain as a
motivator for continued use; weight-linked motivation is cited by women at double the
rate of men. Likewise, they found that women were more liable to resume smoking after
quitting due to weight gain. Finally, in a study of college students, 39% of women and
25% of men initiated smoking as a tactic for dieting success (Office of the Surgeon
General, 2001 ).
In a study of cocaine abusers, Cochrane, Malcolm, and Brewerton (1998) found
that almost half of women presenting for cocaine abuse specifically used cocaine as a
weight control measure; 72% of these were identified as meeting criteria for an eating
disorder. Similarly, Jonas, Gold, Sweeney, and Pottash (1987) diagnosed eating disorders
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in one-third of a sample of callers to the National Cocaine Hotline, via a structured
clinical interview. In addition to appetite suppression, feelings of power and control
initiated by cocaine have been identified as a motivator for use by women with eating
disorders (National Center of Addiction and Substance Abuse (CASA) at Columbia
University, 2003). Parks, Saewyc, Cox and MacKay (2008) found associations with
stimulant use (i.e., amphetamines, cocaine, or cigarettes), disordered eating, and body
dissatisfaction in the general population. In a sample of 30,000 British Columbian
students, they found that individuals who had poor body image, hinged, purged, or dieted,
had a significantly higher likelihood of using stimulants than those who did not. Purgers
were four times more likely to use stimulants than non-purgers; bingers, dieters, and
those dissatisfied with their body were approximately twice as likely to use stimulants
than their counterparts.
The stimulants methylphenidate and dextroamphetamine, both of which are used
to treat Attention Deficit and Hyperactivity Disorder (ADHD), are also utilized for
nonmedical purposes by individuals seeking weight loss. Williams, Goodale, ShayFiddler, Gloster, and Chang (2004) analyzed the misuse of these substances in 450
adolescents referred for treatment. They found that having an eating disorder and not
attending school were the only two predictors which discriminated between stimulant use
and other drug use; however, the effect size was small (R2 = .075). Dukarm (2005)
examined six individuals with bulimia nervosa and comborbid ADHD who were
administered dextroamphetamine as a treatment for both. Patients self-reported a
complete lack ofbingeing and purging behaviors while on the drug. However, it was
unclear as to whether the prescribed stimulant was truly alleviating the eating disorder
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symptomatology, or if it was enabling more severe caloric restriction and thus
extinguishing the binge-purge cycle.
Neurologically, Vicentic and Jones (2007) have tied cocaine- and amphetamineregulated transcript peptides to both food and drug related rewards, which provide
additional evidence to the link between stimulants and eating disorders. CART peptides
regulate the mesolimbic dopamine system, which is associated with feeding and
addiction. Although the temporal precedence of eating disorder symptomology and
stimulant use has yet to be thoroughly investigated, the literature suggests that stimulant
use may serve a particular purpose or function (e.g., appetite suppression) among
individuals with body dissatisfaction or eating disordered symptomatology.
Specific eating disorder symptoms (e.g., restriction, bingeing, purging)
demonstrate unique relationships to different types of substance use. Bulik et al. (1992)
found that individuals with BN or ANbp had significantly higher use of cigarettes (Odds
Ratio (OR)= 6.33), alcohol (OR= 6.61), laxatives (OR= 7.15), amphetamines (OR=
5.38), cocaine (OR= 7.03), and marijuana (OR= 4.54), relative to those with ANr.
Purging, via laxative use, was associated with significantly higher use of emetics,
marijuana, and amphetamines, when compared to non-laxative users. Wiederman and
Pryor (1996) associated amphetamine use with increased caloric constraint; the study
does not make causal claims; however, it may be that stimulant use enabled greater
constraint. Purging was associated with cocaine, cigarette, and poly-drug use.
Additionally, purgers were three and a halftimes more likely to use amphetamines and
cocaine, and four times more likely to smoke, compared to non-purgers (Parkes, Saewyc,
Cox, & MacKay, 2008). Finally, Piran and Robinson (2006, 2011) found that dieting and
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purging were associated with the use of stimulants and abuse of sleeping medication, in
two community samples. Given effect sizes, caloric constraint and purging,
independently ofbingeing, have a clear and strong relationship to stimulant use. These
two eating disordered behaviors will be used to explore possible patterns of comorbidity
associated with stimulant use.
Bingeing behaviors, unlike caloric constraint and purging, were generally
associated with tranquilizer use, hallucinogens (Wiederman & Pryor, 1996), and alcohol
use (Piran & Robinson, 2006; Wiederman & Pryor, 1996). Pure restriction was generally
associated with less drug, alcohol, and psychotropic abuse or dependence than restriction
with binge-eating and purging, or bingeing and purging alone (Corcos et al., 2001; Stock,
Goldberg, Corbett, & Katzman, 2002). Therefore, purging and caloric constraint appear
to be uniquely associated with stimulant use.
Substance Use and Associated Psychopathology
Historically, men were identified as having higher rates of substance use than
women; however, recent clinical studies note a change in this trend. In a review of
epidemiological surveys on substance abuse, Greenfield et al. (20 10) reported that men
continue to use cannabis, alcohol, heroin, and nicotine at higher rates than women.
However, differences between genders have increasingly lessened over time. They noted
similar rates of stimulant use between genders and evidence of equal or higher rates of
nonmedical opioid use in women. The use of stimulants by women appears to be
increasing more rapidly than other types of substances. This increase in stimulant use in
women is evinced by tripled admission rates in federally funded treatment centers for
pregnant women between 1994 and 2006, compared to doubled admissions for stimulant
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treatment in the general population between 1995 and 2005. They also found associations
between substance use and several psychological disorders (e.g. mood, anxiety, and
eating disorders), with women who use substances having significantly more psychiatric
diagnoses than men. These findings suggest that stimulant use is a growing problem
among women and that patterns of comorbidity associated with stimulant use warrant
further investigation.
Chen et al. (20 11) examined psychiatric comorbidities associated with specific
types of substance use by gender in an inpatient treatment sample (N = 465). In females,
the most common comorbidity was cocaine dependence and "any other psychiatric
disorder" (Male/Female odds-ratio= .54). Of women who used cocaine, comorbid
diagnoses were mood disorders (32.6%), anxiety disorders (31 .1%), psychotic symptoms
( 13.1%), Borderline Personality Disorder (27. 7%), and Antisocial Personality Disorder
(12.2%). These psychiatric comorbidity rates were greater than with any other type of
drug.
Stimulant use was also associated with depression. Bohnert and Miech (20 10)
reported increases in the association between cocaine use and depressive disorders
between the 1980's (Odds Ratio (OR)= 1.28) and 1990's (OR= 3.53). Of treatmentseeking cocaine users, depression was noted as one of the most frequent co-occurring
psychological disorders (Kleinman et al., 1990; Rounsaville et al., 1991 ); further, many
treatment-seeking users suffered from subclinical levels of depressive symptomatology.
Additionally, depressed cocaine users reported greater euphoria associated with cocaine
administration than nondepressed users, suggesting that cocaine use may be motivated or
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maintained by a desire to alleviate negative emotions (Newton, Kalechstein, Tervo, &
Ling, 2003; Uslaner, Kalechstein, Richter, Ling, & Newton, 1999).
Levental et al. (2010) reported that anhedonia, defined as diminished interest and
pleasure in rewarding activities, had a particular relationship to stimulant use in a crosssectional, population based sample (N = 43,093). Specifically, they found a distinct
relationship between stimulant use or dependence with anhedonia and depressed mood
across stimulant types (e.g. amphetamine, cocaine). Further, the relationship remained
significant after controlling for demographic, psychiatric, and non-stimulant substance
use characteristics. Odds ratio effect sizes were relatively large, as those using
amphetamines were 3.31 times more likely to exhibit anhedonia, whereas those using
cocaine were 2.56 times more likely to exhibit anhedonia. The effects were partially
attenuated with the introduction of controls; however, they remained in the medium to
high range.
Although these studies demonstrate an association between stimulant use and
depression, there is a dearth of literature comparing depression severity among specific
types of substance use disorders, with only one study directly comparing psychological
comorbidities among different typologies of substances. Nevertheless, this literature
suggests that stimulant users may display elevated rates of depression relative to other
drug users.
Marken et al. (1992) found that marijuana and stimulants were the most
commonly used illicit substances taken by inpatient individuals with manic symptoms.
Similarly, Winokur et al. (1998) found that alcohol and stimulant abuse rates were
significantly higher among bipolar groups than in unipolar or control groups. Stimulant
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use is also being investigated as a potential treatment for bipolar disorder (Pagano,
Demeter, Faber, Calabrese, & Findling, 2008; Wingo & Ghaemi, 2008). It is possible that
those presenting with stimulant use may have elevations on scales measuring mania,
though they may not actually present with bipolar disorder. Stimulant use and mania are
associated with similar symptoms (e.g. decreased need for sleep, racing thoughts), and
measures may not be able to differentiate between the two disorders.
Stimulant users also demonstrate elevations in anxiety sensitivity and anxiety
disorders. Buckner, Proctor, Reynolds, Kopetz, and Lejuez (2011) found that anxiety
sensitivity had a significant association to cocaine dependence; the relationship remained
significant even when controlling for sex, age, alcohol dependence, hallucinogen
dependence, major depressive disorder, panic disorder, and posttraumatic stress disorder.
Herrero, Domingo-Salvany, Torrens, Brugal, & I.T.I.N.E.R.E. (2008) found that anxiety
disorders were the second most common comorbidity (13%) among cocaine-users,
surpassed only by mood disorders (26.6%; see also: Chen et al., 2011). Although there is
a scarcity of research regarding the association between specific types of anxiety
disorders and stimulant use, as well as the role of other types of substances, the literature
indicates that stimulant users may have elevations in general measures of anxiety, relative
to other types of drug users.
In a review of stimulant use and psychosis, Curran, Byrappa, and McBride (2004)
found evjdence for brief psychotic states brought on by large doses of stimulant drugs,
which resolved within a few hours. They additionally found that the presence of positive
symptoms of psychosis prior to stimulant use resulted in increased symptom severity
upon initiation of stimulant use. However, the review noted two studies in which the
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chronic use of injectable stimulants resulted in increased rates of chronic psychosis, with
continued symptomatology long after stimulant use was discontinued (see also: Dawe et
al., 2009; Shoptaw et al., 2009). Subsequent studies reported that 'chronic' or persistent
psychosis among stimulant users was predicted by the early onset of stimulant use and
extended duration of use (Chen et al. 2003; Lichlyter, Purdon, & Tibbo, 2011).
Certain personality traits may be conceptualized as risk factors for substance use
disorders. Grekin, Sher, and Wood (2006) found that specific personality patterns were
predictive of certain types of substance misuse. Namely, antisociality, novelty seeking,
conduct disorder symptoms, and neuroticism were predictive of a variety of substance
misuse. They additionally found unique personality patterns associated with alcohol,
nicotine, and general drug use. For example, alcohol use symptoms were predicted by
high extraversion and low openness, drug symptoms were predicted by low
conscientiousness, and tobacco symptoms were predicted by high openness and low
conscientiousness. Similarly, Kotov, Gamez, Schmidt, and Watson (2010) found that of
the 'Big Five' personality traits, only disinhibition was associated with substance use. A
high level of novelty seeking was associated with significantly greater stimulant use, with
stimulant users being motivated by obtaining positive rewards (Adams et al., 2003). In a
review of neuroimaging studies of stimulant users, Li and Sinha (2008) noted that
stimulant use was associated with brain activity suggestive of impairments in cognitive
inhibition and emotion regulation, as well as in increased impulsivity. In a review
comparing stimulant and opioid addiction, Badiani et al. (2011) reported that in multiple
animal studies, rats who later developed stimulant addictions demonstrated unique
elevations in trait impulsivity prior to initiation of stimulant use; stimulant use
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administration resulted in increased expression of impulsivity. The relationship with
impulsivity was not found in opioid addicted rats.
Valila (2008) attempted to differentiate personality traits between participants
who identified CNS stimulants, depressants, or opioids as their drug of choice. He found
a large effect (Partial Eta Squared = .85) for drug of choice on personality trait scores.
Specifically, participants who engaged in CNS stimulant use were significantly higher on
the Extraversion domain, whereas CNS depressant and opioid users were higher on the
Neuroticism domain than stimulant users. Thus, distinct personality traits are associated
with specific types of substance use. Stimulant use will likely be associated with
personality disorders in which reward seeking, extraversion, disinhibition, impulsivity,
and emotion dysregulation are emphasized. When these personality traits are considered
in the context of other cognitive and behavioral changes associated with stimulants (e.g.,
transient psychosis, paranoia, & aggression), the overall clinical picture is suggestive of
borderline personality disorder.
Stimulant use is associated with specific personality disorders, namely, antisocial
.

.

.

personality disorder and borderline personality disorder. Paim-Kessler et al. (2012) found
that crack users presented with significantly higher rates of antisocial personality
disorder, relative to both powder cocaine and other psychoactive substance users.
Furthermore, Echeburtia, DeMedina, and Aizpiri (2009) compared personality disorders
among individuals presenting with pure alcohol dependence and comorbid cocaine abuse
and alcohol dependence. Individuals presenting with comorbid cocaine abuse had
significantly higher rates of antisocial (21%), narcissistic (14.5%), and borderline
(11.3%) personality disorders, relative to individuals with pure alcohol use. However,
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borderline personality disorder, followed by other cluster B disorders, were also the most
common personality disorders in all individuals presenting for substance use treatment
(Ray, Primack, Chelminski, Young, & Zimmerman, 2011). Furthermore, Feske, Tarter,
Kirisci, and Pilkonis (2006) found that borderline personality disorder was a significant
predictor for multiple categories of substance use, including: any substance use disorder,
alcohol use, drug use, heroin, cocaine, or poly-substance use. Antisocial personality
disorder emerged as a partial mediator of the relationship between borderline personality
disorder and substance use disorders. Thus, stimulant use is associated with increased
rates of antisocial and borderline personality disorders across several studies; only one
study found an association to narcissistic personality disorder. However, the high rates of
these personality disorders across substance use types may obscure particular
relationships.
The literature suggests that individuals who use stimulants, relative to other types
of substances, may present with increased prevalence or severity of mood disorders,
psychotic disorders, and borderline and antisocial personality disorders. Additionally,
individuals using stimulants may have elevations in core symptoms of anxiety; however,
the relationship between specific anxiety disorders and substance use disorders remains
unclear. Of note, the preponderance ofthe research examined the relationships between
only two individual constructs at a time, which prevents the identification of common
clusters of disorders and those disorders which may demonstrate greater impact or
relevance to individuals who use specific types of substances.
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Eating Disorders and Associated Psychopathology
Given the strong link between stimulant use and particular eating disorder
behaviors such as caloric constraint and purging (Parkes et al. , 2008; Piran & Robinson,
2006 & 2011; Wiederman & Pryor, 1996), it is important to examine psychopathology
associated with these behaviors, as it may influence the clinical pattern found in stimulant
users. In a review of the literature, Pearlstein (2002) found that major depression and
dysthymia were highly prevalent across eating disorder types and subtypes. In a separate
review, O'Brien and Vincent (2003) found that the highest rates of depression occurred in
the ANbp subtype; given that this subtype is defined, in part, by caloric constraint and
purging, depression and stimulant use may be linked through eating disordered
psychopathology (see also review: Casper, 1998). Purging, alone or with bingeing, was
consistently linked to increased levels of depression when compared to other types of
eating disorder behaviors (Garner, Garner, & Rosen, 1993). These findings give added
support to the hypothesis that stimulant use will result in higher levels of depression than
other drug use, given the association between stimulant use, purging, and caloric
constraint.
In a review of the literature, Pearlstein (2002) reported that eating disorders have
not generally been linked to bipolar disorder, citing only three studies in the last twenty
years. In a few instances, elevations in bipolar II were linked specifically to BN;
similarly, rates of eating disorders were found to be minimally elevated in a bipolar
sample. Therefore, although stimulant use alone has associations with mania, the
literature suggests that eating disorder symptomatology may not have a role in these
findings.
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Anxiety disorders, specifically obsessive-compulsive disorders and social
phobias, were commonly associated with eating disorders and substance use disorders.
Lifetime prevalence rates range from 20-55% in AN and 13-75% in BN (Bulik et al.,
1992; Pearlstein, 2002). Social phobias appeared to occur equally in AN and BN,
whereas obsessive compulsive disorder occurred more in AN (Pearlstein, 2002). For
individuals in treatment for substance use disorders with eating disorder symptoms,
posttraumatic stress disorder (PTSD) symptoms were significantly higher in those who
reported bingeing (Cohen et al., 2010). Spindler and Milos (2007) found that binge-eating
and purging behaviors were linked to increased anxiety (Odds Ratio = 1.90 - 2.22) and
substance use (OR= 1.65 for vomiting, 1.89 for bingeing, and 4.23 for laxative use).
Similarly, they found that dieting and fixation on being underweight was related
specifically to anxiety disorders (OR = 4.23); weight and appearance concerns were
concomitant with affective (OR = 1.81) and anxiety (OR = 2. 77) disorders. Given the
association of stimulant use with caloric constraint and purging, findings indicate that
stimulant use may be associated with increased symptoms of anxiety. However, specific
types of anxiety disorders may not demonstrate a consistent relationship with stimulant
use.
The personality trait of obsessionality may serve as a protective mechanism
against substance use disorders in individuals with eating disorders (Thompson-Brenner
et al. , 2008). Vitousek and Manke (1994) found that individuals diagnosed with AN were
often identified as restrained, compliant and obsessional. Those diagnosed with BN were
less consistent in personality, though affective instability and impulsivity were
particularly common. In a review, Pearlstein (2002) found the previous associations as
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well as stress reactivity, affective dysregulation, impulsivity, novelty seeking, low selfesteem and interpersonal sensitivity in those with BN (see also reviews: Lilenfeld et al.,
2000; Wonderlich & Mitchell, 2001); those with AN were further associated with
perfectionism and negative self-evaluation.
Personality disorders were likewise linked to specific eating disordered behaviors,
which in turn have particular relationships to stimulant use (e.g. caloric constraint,
purging). Borderline personality disorder was consistently linked to bingeing and purging
behaviors in AN binge-purge type and BN, at rates ranging from 33% to 71% (O'Brien &
Vincent, 2003; Pearlstein, 2002; Rosenvinge, Martinussen, & Ostensen, 2000). Similarly,
Spindler and Milos (2007) found that binge-eating and purging behaviors were linked to
increased cluster B personality disorders (OR = 2.12- 2.65).
Rosenvinge et al. (2000) performed a meta-analysis of studies regarding
personality disorders and eating disorders from 1983 to 1998. They found that cluster C
personality disorders (i.e. dependent, avoidant, obsessive-compulsive) occurred in equal
rates across eating disorders, at rates of approximately 45%. Additionally, they found that
cluster A disorders (i.e. paranoid, schizoid, and schizotypal) had a higher prevalence in
BN, at 27%, compared to 12% of AN patients. In cluster B disorders (i.e. narcissistic,
borderline, antisocial, and histrionic), BN (44%) was likewise higher than AN (15%). In
a review of the literature, Pearlstein (2002) reported that AN was most commonly
associated with avoidant personality disorder, whereas BN was most commonly
associated with borderline personality disorder. Additionally, borderline personality
disorder was specifically associated with the purging subtype of EDNOS (e.g. Purging
Disorder).
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A few authors utilized multivariate analysis to examine psychopathology
associated with specific eating disordered types and behaviors. Craig (1997) examined
the personality and clinical scales of the MCMI-III in a group of eating disordered
patients (N = 70). Discriminate analysis determined that the Dysthymia, Major
Depression, and Thought Disorder scales discriminated the AN and AN binge/purge type
from the BN and EDNOS groups (SCC = .41). Given that the ANbp subtype is partially
defined by purging and caloric constraint, the Dysthymia, Major Depression, and
Thought Disorder scales of the MCMI-III may also demonstrate elevations among
stimulant users. Ciccolo and Johnsson (2002) identified three clusters of associations with
eating disordered behaviors. The cluster associated specifically with purging, in isolation
or with bingeing, had elevated levels of aggression and somatization, as well as lower
levels of interoceptive awareness. Similarly, Garner et al. (1993) associated purging with
greater levels of depression, panic disorders, anxiety, and suicide attempts. Given the
association between purging and stimulant use (Piran & Robinson, 2006; 2011), these
forms of psychopathology may be similarly elevated among stimulant users.
The literature suggests the eating disordered symptoms associated with stimulant
use may be related to increased depression, general anxiety, thought disturbance, and
borderline personality disorder, compared to eating disorder symptoms associated with
other types of substances. As the vast majority of studies examined the confluence of two
disorders at a time, despite the multiple comorbidities associated with stimulant use, the
relative importance of a given disorder to the overall clinical presentation remains
unclear.
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The Present Study
There is considerable literature demonstrating associations between substance
use, eating disorders, personality disorders, and other clinical syndromes, but almost
always relating two groups of disorders at a time (e.g., eating disorders and substance
use). There is also evidence in the literature that.comorbidities between any pair of
disorder groups predicts poorer prognosis and that various combinations may respond
differently to treatment modalities. In treatment settings, patients may present with more
than two comorbid disorders. For example, it is not uncommon for substance use to be
comorbid with eating disorders, personality symptoms, depression, and anxiety. Such
complicated cases can be very difficult to treat and even more challenging in the
development of a case formulation. Identification of common clusters of comorbidity is a
logical first step toward clarifying the complex relationships among these multiply
comorbid cases, which may in turn allow identification of specific intervention strategies
to more effectively treat specific comorbid combinations.
The present study examines differences in personality, psychopathology, and
eating disorder symptomatology between women who use stimulants compared with
women who use other types of drugs. In the literature, stimulant use has been associated
with specific types of psychopathology and eating disorder behaviors (Table 1),
particularly mood disorders, anxiety, psychosis, borderline and antisocial personality
disorders, caloric constraint, and purging. Similarly, the eating disorder behaviors
associated with stimulant use are associated with elevations in depression, anxiety,
thought disturbance, and borderline personality disorder. Therefore, stimulant use is
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predicted to be associated with higher overall levels of psychopathology and personality
symptoms; specifically, stimulant users will have significantly higher mood and anxiety
scores, thought disturbance/psychosis scores, and borderline and antisocial personality
scores. Additionally, stimulant use is predicted to result in higher eating disorder
pathology, and thus elevated scores on the EDI-3 risk composites and the associated
psychological scale (i.e., Emotion Dysregulation).
Table 1
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Table 1 (continued).

I
Novelty
Seeking
Suicide
Attempts
Aggression
Concern with
body/ weight
Eating
Disorder

Stimulant
use
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AN
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BED
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ANbp
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Thought Dist.: Thought Disturbance
Other Clust. 8 : Other Cluster B
Emotion Dys.: Emotion Dysregulation
Note: Individual studies are counted from each review, to prevent under or over examination of relationships

The current study is particularly valuable, as there is a dearth of literature
regarding patterns of multiple comorbidity associated with particular types of substance
use. Relatively few studies have examined differences in presentation based on substance
use type, with even fewer studies examining these presentations multivariately. If
expected differences are found, the current study may indicate the need to establish
specific treatment modalities based on comorbid eating disorder and substance use
combinations.
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CHAPTER II
METHODOLOGY
Subjects
Subjects were a convenience sample of women at a residential treatment center
for women with substance use disorders, with and without comorbid eating disorders.
Although the current sample contained a portion of women with AN, BN, and EDNOS
diagnoses, all of these women had the central feature of binge eating or purging. There
were no pure restrictors in this sample. The target population for the current study was
women who engage in substance use. Although all women were being treated for
substance use disorders with or without comorbid eating disorders, not all women will
meet the clinical level for both diagnoses. All data gathered were part of standard
assessments given upon admission to the treatment facility. Subjects were from various
locations across the United States, though all obtained treatment in the southeastern
United States.
The present study included a mix of approximately 70 archival participants and
approximately 50 voluntary participants, for a total of 124 female participants. Archival
data was obtained between December 2009 and October 2012, and was de-identified at
the treatment facility before being released for research. It was not feasible to contact
these patients individually; however, permission was granted by two Institutional Review
Boards (Appendix A) before utilizing data from these patients. All participants entering
the study from November 2012 to March 2013 gave informed consent for their data to be
utilized in the study, with the understanding that their participation, or lack thereof,
would in no way affect their treatment.
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As effect sizes were consistently large within the literature, effects were expected
to be large within the current study. Power analysis indicated that with a large effect size,
92 to 106 participants would be sufficient to capture group differences.
Procedure
All assessments were given by a mental health clinician, as part of standard intake
procedures. Furthermore, a certified addictionologist interviewed each patient regarding
their substance use. A mental health clinician completed a clinical interview to determine
diagnoses for each participant, using DSM-IV-TR (APA, 2000) criteria. An onsite chartreview was completed for each participant, within the security parameters of the facility.
The chart review was utilized to determine diagnoses, frequency, intensity, duration, and
type of substance use, and to obtain scores from the assessment instruments. Between
November 2012 and March 2013, all patients were informed that with their consent, their
data would be used for both research and treatment planning. Upon verbal agreement by
the patient to participate in the study, the clinician signed and dated the informed consent
to maintain the patient's privacy. This precaution was utilized as an additional security
measure, ensuring that there was no possible data trail leading back to the patient's
identity. The consent forms and data were stored separately in locked filing cabinets,
within the security parameters of the institution.
Instruments
Three instruments will be utilized in the present study: the Eating Disorder
Inventory-3 (EDI-3; Garner, 2004), the Personality Assessment Inventory (PAl; Morey,
1991) and the Millon Clinical Multiaxial Inventory-III (MCMI-111; Millon, Millon,
Davis, & Grossman, 2009). The EDI-3 will be utilized to determine eating disordered
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behaviors and associated symptomology, whereas the PAI and MCMI-III will be utilized
to determine elevations of particular personality disorders and psychopathology (e.g.
depression and anxiety disorders).
Eating Disorder Inventory-3
The EDI-3 is a 91 item self-report instrument which measures psychological and
behavioral traits common to eating disorders. The instrument is designed to be used as an
aide to diagnosis, in conjunction with clinical interviewing, and as an outcome measure
and research tool (Gamer, 2004).
Gamer (2004) details three Eating Disorder Risk scales: Drive for Thinness,
which measures terror of weight gain and yearning for thinness; Bulimia, which measures
rumination and behaviors relating to binge eating; and Body Dissatisfaction, which
examines displeasure with shape and body mass. Gamer (2004) also details eight
psychological scales: Low Self-Esteem, which measures negative self-appraisal and
feelings of insecurity; Personal Alienation, which assesses an impoverished selfunderstanding; Interpersonal Insecurity, which measures reservation and distress in social
circumstances; Interoceptive Deficits, which evaluates misperceptions in correctly
identifying and reacting to emotional cues; Emotional Dysregulation, which assesses
impulsivity, volatility, anger, and substance misuse; Perfectionism, which assesses
personal and goal achievement; Asceticism, which evaluates self-denial and control; and
Maturity Fears, which measures the wish to return to childhood and maintain a
prepubertal fa<;ade (Gamer, 2004).
Gamer (2004) reported that the EDI-3 was normed both nationally and
internationally for Anorexia Restricting, Anorexia Binge/Purge, Bulimia, and Eating
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Disorder not Otherwise Specified, as well as for adult and adolescent clinical populations.
Additionally, Podar and Alik (2009) assessed 301 participants differing on sex, age,
diagnosis, language and ethnicity, and examined the factorial structure of the EDI
subscales. They found almost indistinguishable structures across clinical and non-clinical,
as well as Western and non-Western participants, indicating that the EDI-3 is
generalizable across cultures.
Gamer (2004) reported that the internal consistency coefficients ranged from the
.80s to the .90s for the three Eating Disorder Risk scales and eight psychological scales,
across the three normative groups and four diagnostic categories. Additionally, they
reported the median test-retest coefficients for the Eating Disorder Risk scale as .95 and
the Psychological scales as .93 . Finally, they reported that validity was established
through the use of factor analysis and intercorrelational studies with external eating
disorder measures (e.g., the EAT-26 and BULIT-R) and with external measures of
personality and psychopathology (e.g., the Rosenburg Self-Esteem Scale and MCMI-II).
The EDI-3, therefore, should be a reliable and valid measure of eating disorder symptoms
and psychological features in this group of substance using women in residential
treatment.
Millon Clinical Multiaxial Inventory-III
The MCMI-III is a 175 item self-report measure, which is designed to be
completed in 20 to 30 minutes and can be administered in an individual or group setting.
The MCMI-III contains 27 scales: 24 Clinical scales, which are delineated based on
severity and according to Axis I and Axis II disorders, as well as three Modifying
Indices, measuring disclosure, desirability, and debasement.
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Millon et al. (2009) delineate 11 scales measuring personality patterns: Schizoid,
which measures detached, apathetic, and asocial characteristics; Avoidant, which
measures caution and anxiety regarding possible social rejection; Depressive, which
assesses chronic glumness, pessimism, and an inability to experience pleasure;
Dependent, which measures passiveness and a need for guidance; Histrionic, which
measures need for attention, fear of isolation, and relational manipulation; Narcisstic,
which assesses egotism, arrogance, and willingness to engage in exploitation; Antisocial,
which measures deception, impulsivity, and engagement in illegal activities for personal
benefit; Sadistic, which assesses gratification from the degradation and violation of
others; Compulsive, which evaluates perfectionism and discipline, fear of reproach, and
antipathy towards others; Negativistic, which measures passive aggressiveness; and
Masochistic, which assesses fostering of self-exploitation and self-debasement.
Furthermore, Millon et al. (2009) delineate three scales which measure severe
personality pathology, which were devised to encompass increased deterioration in
personality, including social and psychotic deficits. The Schizotypal scale measures
intentional isolation, selfishness, emotional blunting, and emotional guardedness. The
Borderline scale assesses emotional lability, uncertain self-image, and paradoxical
interpersonal relationships. The Paranoid scale assesses pervasive suspicion and mistrust
of others, recalcitrance, and inflexibility.
Millon et al. (2009) outline seven scales which measure moderately severe
clinical syndromes: Anxious, which measures many forms of anxiety (e.g., specific
phobias, somatic complaints, hypervigilance); Somatoform, which measures the
expression of psychological complaints through body complaints; Bipolar: Manic, which
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assesses manic symptomatology (e.g., agitation, impulsivity, and restlessness);
Dysthymia, which evaluates apathy, chronic fatigue, social withdrawal, and anhedonia;
Post-Traumatic Stress, which captures reaction to trauma and anxious arousal; Alcohol
Dependence, which measures issues with alcoholism, recovery failures, and social
consequences; and Drug Dependence, which assesses a recurrent or recent history of drug
abuse, as well as impulsivity, and social and personal consequences.
Finally, Millon et al. (2009) outline three scales which measure severe clinical
syndromes. The Thought Disorder scale assesses disoriented, schizophrenic-like
symptoms, such as hallucinations, delusions, disorganized thought and emotional
blunting. The Major Depressive scale measures severely depressed, hopeless, and
suicidal behaviors and cognitions. Finally, the Delusional Disorder scale examines
antagonistic and paranoid delusions, along with disturbed thinking.
Millon et al. (2009) noted that the MCMI-III underwent a three-step validation
process, including 1) theoretical-substantive, 2) internal structure, and 3) externalcriterion. The validation process was sequential, with items having to meet the criteria for
each step before they could be evaluated in the next step. The revision process utilized
several hundred clinicians who previously utilized the MCMI-II, across 26 states and
Canada, for a total sample of 998 subjects. These subjects included individuals from
inpatient and outpatient treatment centers, correctional facility inmates, and college
student counselees.
Millon et al. (2009) reported that across the Clinical Personality Patterns, Severe
Personality Pathology, Clinical Syndromes, and Severe Clinical Syndromes scales,
internal consistency alpha levels ranged from .66 (Compulsive scale) to .90 (Major
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Depression), with scores exceeding .80 for 19 ofthe 24 scales. Additionally, test-retest
reliability was established through re-administration of the MCMI-III to 87 individuals,
over 5-14 days. Stability coefficients range from .84 to .96 for these 24 scales. Finally,
the MCMI-III was correlated with a number of external measures, including the Beck
Depression Inventory, Symptom Checklist-90-Revised, MMPI-2, and Michigan
Alcoholism Screening Test.
Personality Assessment Inventory
The PAl (Morey, 2007) is a 344 item, self-report inventory which measures adult
psychopathology and personality. Morey (2007) describes 11 clinical scales, five
treatment scales, 2 interpersonal scales and 4 validity scales, which together comprise the
22 scales of the inventory. For the purposes of this study, only the clinical scales and one
treatment scale will be utilized. Results are reported as t-scores, with scores above 70
falling in the clinical range.
Morey (2007) delineates 11 clinical scales: Somatic Complaints, which measures
a preoccupation with physical complaints; Anxiety, which measures cognitive,
physiological, and affective symptoms of anxiety; Anxiety-Related Disorders, which
assesses anxiety related to phobias, traumatic stress, and obsessive compulsive disorder;
Depression, which evaluates cognitions, emotions, and physiological symptoms
associated with depression; Mania, which measures irritability, grandiosity, and activity
level; Paranoia, which measures persecution, resentment, and hyper-vigilance;
Schizophrenia, which evaluates psychotic experiences, social detachment, and thought
disorder; Borderline, which assesses affective instability, identity problems, and selfharm; Antisocial, which measures criminal behavior, stimulus seeking, and egocentricity;
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and Alcohol Problems and Drug Problems, which measure substance use and
dependence, as well as problems and consequences related to use.
Morey (2007) describes five treatment scales established to measure the
willingness to engage in treatment as well as complicating factors related to treatment.
For the purposes of this study, only the Suicidal Ideation scale (i.e., measuring suicidal
ideation, plans) wasused.
Morey ( 1996) reported that the P AI was developed for use in both normative and
clinical populations, in adults aged 18 years or above. The standardization sample was
representative and modeled after the United States census. The internal consistency
alphas were a median of .81, .82, and .86, for normative, college, and clinical
populations. In substance using populations, median alpha levels for the full scales were
.78 for a methadone-using sample (Alterman et a!., 1995) and .86 for an alcoholic sample
(Schinka, 1995). In an eating disordered sample, the mean reliability of the full scales
was .82 (Tasca, Wood, Demidenko, & Bissada, 2002). For temporal stability, the median
test re-test reliability was .86 in the standardization sample, with a four week interval
between the test and retest (Morey, 1996).
Morey (1996) accumulated data regarding convergent and discriminant validity
correlates in order to establish the construct validity of the P AI scales. He reported
correlations of the individual scales with more than 50 concurrent indices of
psychopathology. Additionally, validity scales were developed to ascertain efforts
towards impression management and strategic or careless responding. Inconsistency and
careless responding was addressed through 1,000 computer simulations of random
responses; 99.4% of these 'simulations' were identified by the scales. Finally, these

30
validity scales were correlated with other suc:h scales on similar measures, with
correlations ranging from .4 to .6.
Statistical Plan
The data obtained in the present study were analyzed using a combination of
descriptive and inferential methods. The independent variable was dichotomous and
measured the presence or absence of stimulant use, with the understanding that an
absence of stimulant use still implied the presence of other types of drug use. Substance
use was ascertained on the basis of the addictionologist's report, from the chart review.
Due to the nature of the research, it was not possible to randomly assign participants to
groups, nor was there a practical way to ensure equal group sizes.
The hypotheses for the study were analyzed using multivariate analysis of
variance (MANOVA) and descriptive discriminant function analysis (DDA). MANOVA
was used to determine if there were mean differences between the two substance use
groups (i.e., stimulant use versus 'other drug' use) on the scales of the EDI-3 , MCMI-III,
and PAL Descriptive discriminant function analysis (DDA) was utilized to further assess
the ability of each set of scales to discriminate between the two substance use groups. In
essence, it was a multivariate follow-up to the omnibus test of significance found from
the MANOVA. Univariate analyses were examined following the discriminant analyses;
however, the focus ofthe analyses will be on the results ofthe MANOVA and DDA in
order to minimize Type 1 error (Stevens, 2002).
A number of statistical tests were used to ensure that statistical assumptions were
met and to report the results ofMANOVA and DDA. First, multivariate normality was
assessed by ascertaining univariate normality (e.g., removing outliers, checking
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histograms, measures of central tendency, and standardizing skewness and kurtosis
values). Secondly, multivariate analysis was tested using the Mahalonbis's Distance
statistic (Meyers, Gamst, & Guarino, 2006). Homogeneity of covariance matrices was
tested using Box's test (Field, 2009) for MANOVAs; this assumption was further
assessed in DDA by comparing the log determinants to ensure they were in the same
ballpark (Huberty, 2002, pp. 587-588). With regards to univariate assumptions,
homogeneity of variance was assessed using Levene's test; violations to this test were
followed up with FMax tests (Field, 2009). If a scale grossly violated this assumption, it
was not be interpreted at the univariate level. Given the nature of this data, Pillai's trace
was used as the multivariate test statistic as it is the most robust to potential issues with
heterogeneity of variance and covariance (Meyers et al., 2006). Bonferroni corrections
were employed for alpha levels for both multivariate (p < .017) and univariate analyses (p
< .001) in order to guard against Type 1 error (Meyers et al., 2006). Partial eta squared
was utilized as an effect size for the MANOVAs, eta squared was used as an effect size
for the univariate analyses, and canonical r 2 was used as an effect size for DDA (Field,
2009). Finally, with regards to DDA, .30 was used as an interpretive cut-off for structure
correlations (Finch, 2009; Tabachnick & Fiddell, 2001), unless there were severe
violations in the data, in which case .50 was utilized to minimize error (Finch, 2009).
This study employed three planned analyses based on a priori hypotheses. Using
the EDI-3, the Drive for Thinness, Bulimia, Body Dissatisfaction, and Emotion
Dysregulation scales were entered as dependent/outcome variables in a MANOVA and
DDA, with the stimulant use dichotomy as the independent variable. Secondly, using the
P AI, the stimulant use dichotomy was again the independent variable, and the
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Depression, Mania, Anxiety, Schizophrenia, Borderline, and Antisocial scales were
entered as dependent/outcome variables in a MANOVA and DDA. Finally, using the
scales of the MCMI-111, the stimulant use dichotomy was the independent variable, and
the Anxiety, Major Depression, Dysthymia, Bipolar: Manic, Thought Disturbance,
Borderline, and Antisocial scales were entered as dependent/outcome variables in a
MANOVA and DDA. Three heuristic analyses were employed to further extend the
understanding of the relationships between the constructs. The remaining scales of each
measure were entered as dependent variables into three MANOVAs and DDAs, separated
by measure.
All three measures were utilized, despite overlap, as each measure contained
unique information and scales which were not captured by other measures. Therefore,
utilizing the scales of both measures in a single analysis may have resulted in a scale
from one measure taking all of the variance at a multivariate level and masking the
contribution of a similar scale on another measure. Furthermore, inclusion of both
broadband measures permitted comparison of results on overlapping scales, thus
speaking to validity and allowing for examination of the clinical utility of these
instruments.
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CHAPTER III
ANALYSES AND RESULTS
Preliminary Analyses
Data were assessed for normality using measures of central tendency, histograms,
skewness and kurtosis, and z-scores. Among the MCMI data, two participants had
outlying scores across scales; therefore, these two participants were excluded. After this
removal, skewness and kurtosis were calculated and standardized. The data evinced
skewness outside the cut-off of ±3.28 (Field, 2009) in six of the 11 EDI-3 scales, three of
the 13 PAl scales, and 12 ofthe 24 MCMI-111 scales. Kurtosis was outside the cut-off of
±3.28 (Field, 2009) in two of the 11 EDI-3 scales, three of the 13 PAl scales, and two of
the 24 MCMI-111 scales. Therefore, several of the scales demonstrated a non-normal
distribution, which was expected given the clinical population. Data could not be
transformed, however, as data evinced both positive and negative skew, platykurtic, and
leptokurtic distributions depending on the scale; these distribution differences were likely
due to differences in base rates of particular disorders measured by the scales.
Mahalonobis' distance was calculated as a measure of multivariate normality (Meyers et
al. , 2006). Ap participants fell below the critical value ofi (df 49) = 85.35,p = .001 ,
providing eviden~e for multivariate normality. Therefore, although some caution should
be employed in interpreting these results due to violations to univariate normality, there
was evidence supporting the assumption of multivariate normality.
Participants were excluded from analyses due to missing data or invalid profiles;
participant totals ranged from 110 to 114, depending on analysis. Levene's test for
equality of variance was completed for each scale (Table 2). All scales with significant
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results were followed up with Hartley's FMax test (Field, 2009). The critical value for the
FMax test, given the smaller of our two group sizes (N = 31) and a = .05 , was 2.63. The
variance ratios for the following scales exceeded the critical values for the FMax test:
Suicidal Ideation (2.84), Anxiety (6.10), Sadistic (2. 79), Negativistic (3.02), Masochistic
(2.98), and Posttraumatic Stress (4.07). Although each ofthese scales violate the
assumption of equality of variances, the Anxiety and Posttraumatic Stress scales
demonstrated a gross violation and should not be interpreted at the univariate level. The
remaining scales (i.e., Suicidal Ideation, Sadistic, Negativistic, Masochistic) should be
interpreted with caution.
Table 2

Results from Levene's Test for Equality of Variance; All Scales
Dependent Variable

F

DF 1

DF2

Sig.

1
1
1
1

111
11 1
11 1
111
112
112
11 2
112
112
112
112
112

.172
.078
.689
.0 19
.11 6

EDI-3
Drive for Thinness
Bulimia
Body Dissatisfaction
Emotion Dysregulation
Low Self Esteem
Personal Alienation
Interpersonal Inseclirity
Interpersonal Alienation
Interoceptive Deficits
Perfectionism
Asceticism
Maturit~ Fears
PAl
Anxiety
Depression
Mania
Borderline
Antisocial
Somatic Concerns
Anxiety Related Disorders
Paranoia

1.89
3.17
0. 16
5.71
2.51
8.08
0.05
5.52
3.09
. 0.10
1.99
1.24
0.0 1
0.79
0.50
0.60
0.39
4.04
0.04
3.27

1
1
1
1
1
1
1
1
1

1
1
1
1
1
1~

1

111
111
111
111
11 1
111
111
111

.005
.829

.021
.082
.757
.1 61
.269
.926
.376
.483
.441
.536

.047
.848
.073
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Table 2 (continued).
De.eendent Variable
Schizophrenia
Alcohol Concerns
Drug Concerns ·
Aggression
Suicide Ideation
MCMI-111
Anxiety
Bipolar: Manic
Dysthymia
Thought Disorder
Major Depression
Antisocial
Borderline
Schizoid
Avoidant
Depressive
Dependent
Histrionic
Narcissistic
Sadistic
Compulsive
Negativistic
Masochistic
Schizotypal
Paranoid
Somatoform
Alcohol Dependence
Drug Dependence
Posttraumatic Stress
Delusional Disorder

F
9.83
0.65
0.06
2.39
6.79

DF 1
1
1
1

DF2
111
111
111

1
1

111

14.99
2.76
0.92
20.43
0.12
2.90
9.70
6.79
8.81
0.81
12.36
1.39
4.02
19.88
1.353
38.00
11.05
9.26
5.97
1.77
5.65
7.08
16.85
0.31

1
1
1
1
1

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

111

Sig.
.002
.421
.810
.125
.010

109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109
109

.000
.099
.341
.000
.730
.091
.002
.010
.004
.370
.001
.241
.048
.000
.247
.000
.001
.003
.016
.186
.019
.009
.000
.582

*Bolding denotes significance

With regards to drug use, the sample was comprised of29.8% stimulant users,
68.5% alcohol users, 47.6% opioid/opiate users, 28.2% GABA agonists users, 22.6%
marijuana users, and 8.1% 'other' users. Of stimulant users, 2.7% used only stimulants,
32.4% used stimulants and one additional substance, and 64.9% used three or more
classes of substances. Of other drug users, 55.2% used one substance in isolation, 31.0%
used two types of substances, and 13.8% used three or more classes of drugs. With
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regards to eating disorders, 35.5% of the total sample was diagnosed with an eating
disorder, according to DSM-IV criteria. With regards to comorbidities, 59.50% of
stimulant users and 25.3% of all other types of drug users were diagnosed with a
comorbid eating disorder.
Results, EDI-3
Per the a priori hypotheses, stimulant use was dichotomized as a grouping
variable and the Drive for Thinness, Bulimia, Body Dissatisfaction, and Emotion
Dysregulation scales were entered as dependent variables into a MANOVA. Covariance
homogeneity was supported by Box's test, M= 15.57, F(10, 18054) = 1.48, p = .140. The
multivariate model explained a significant portion of the variance in stimulant use,

Pillai's Trace= 0.18 F(4, 108) = 5.83,p < .001 , partial r/ = .18. Subsequently, univariate
analyses were examined. Stimulant use was associated with significantly higher Emotion
Dysregulation, F(l, 111) = 14.51,p < .001, compared to other drug use; Drive for
Thinness, F(1, 111) = 10.42, p = .002, and Body Dissatisfaction, F(1, 111) = 3.93,p =
.05, approached significance but did not meet the p < .001. The Bulimia scale did not
differentiate between stimulant use and other drug use, F (1 , 111) = 2.98,p = .087.
Means and standard deviations are presented in Table 3.
Table 3

A Priori Univariate Analyses, EDI-3
Dependent Variables
Drive for Thinness**
Bulimia
Body Dissatisfaction*
Emotion
Dysregulation** *
Note: *p < .05, **p < .01, ***p < .001

Stimulant Use
(N=33)
40.55/ 14.32
47.09/ 11.28
42.45/ 12.93
56.76/11.14

Other Drug Use
(N = 81)
31.56/12.93
43.63/8.63
37.31/12.22
49.86/7.57

Eta Squared
.08
.03
.03
.11
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Descriptive discriminant analysis (DDA) was used to further assess the ability of
the four eating disorder scales to separate the two grouping variables of stimulant use and
other drug use. Log determinants were relatively equal (Group 1: 16.85, Group 2: 17.60,
Error: 17.21 ), providing further evidence for the homogeneity of covariance matrices.
One function was extracted from the data, A= .82,

i (df 4) = 21.32,p < .001.

The

canonical / was equal to .17, indicating that the discriminant function accounted for
17.7% of the variance.
Standardized canonical discriminant function coefficients (Table 4), which
indicate the strength of a scale's unique contribution to a function, demonstrated that the
function was principally predicted by Drive for Thinness, followed by the Emotion
Dysregulation. Body Dissatisfaction negatively predicted the function. The structure
correlations (Table 4) indicated that Emotion Dysregulation demonstrated the highest
correlation with the function, followed by Drive for Thinness; Body Dissatisfaction and
Bulimia were also correlated to the function, albeit at lower levels. Group centroids, the
standardized means of the two grouping variables, were .72 for stimulant users and -.30
for other drug users. Therefore, stimulant users were characterized by a desire for
thinness in conjunction with dysregulated emotions.
Table 4
A Priori Discriminant Analysis Results, EDI-3
Dependent Variables
Drive for Thinness
Bulimia
Body Dissatisfaction
Emotion Dysregulation

Structure Matrix
(Correlations)
.66

.35
.41
.78

Standardized Discriminant
Function Coefficients
1.04
-0.20
-0.48
0.74
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Per the heuristic hypotheses, stimulant use was dichotomized as a grouping
variable, and the remaining scales of the EDI-3 (e.g., Low Self-Esteem, Interoceptive
Alienation) were entered as dependent variables into a MANOVA. Stimulant use did not
account for a significant portion of the variance in the multivariate model, Pillai 's Trace
= 0.1 0, F (8, 105) = 1.40, p = .207. Due to this lack of significance, univariate analyses
and discriminant analysis will not be further discussed for this model.
Results, PAI
In accordance with a priori hypotheses, the stimulant use dichotomy was entered
as the independent variable and the Anxiety, Depression, Mania, Schizophrenia,
Borderline, and Antisocial scales of the P AI were entered as dependent variables into a
MANOVA. Covariance homogeneity was supported by Box's test, M= 25.338, F(21,
12470) = 1.11, p = .327. The multivariate model explained a significant portion of the
variance in stimulant use, Pillai 's Trace = 0.25, F (6, 106) = 5.75 , p < .OOl,partial r/ =
.25. Univariate analyses indicated that stimulant use was associated with significantly
higher scores on Borderline, F ( 1, 111) = 23.51, p < .001, and Antisocial scales, F ( 1,
111) = 21.65,p < .001, compared to other drug use. Depression, F (1, Ill)= 6.03, p =
.016, Mania, F (l , 111) = 7.54, p = .007, and Schizophrenia, F (l, 111) = 6.85, p = .010
approached significance but did not meet the p < .001 level. The Anxiety scale did not
differentiate between stimulant use and other drug use, F (l, 111) = 2.15, p = .146.
Means, standard deviations, and effect sizes are presented in Table 5.
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Table 5
A Priori Univariate Analyses, PAI

Dependent Variables
Anxiety
Depression*
Mania**
Schizophrenia**
Borderline***
Antisocial***

Stimulant Use
(N=31)
66.84114.10
71.81/ 15.28
54.35/ 10.71
59.65/16.35
75.06/ 13.59
67.55/ 13.07

Other Drug Use
(N = 82)
62.51 /13.96
64.61/13.35
48.73/9.32
52.68/ 10.92
62.21/12.14
54.84/ 12.91

Eta Squared
.02
.05
.06
.06
.18
.16

Note: *p < .05, **p < .01, ***p < .001

DDA was used to determine the ability of the six personality and
psychopathology scales to separate stimulant use from other drug use. Log determinants
were relatively equal (Group 1: 26.09, Group 2: 26.63, Error: 26.47), providing further
evidence for the homogeneity of covariance matrices. One function was extracted from
the data, A = .76, :iCdf6) = 30.42, p < .001. The canonical r 2 was equal to .24,
indicating that the discriminant function accounted for 24.5% of the variance.
Standardized canonical discriminant function coefficients (Table 6) indicated that the
function was principally positively predicted by the Borderline scale, and to a much
lesser extent, the Antisocial and Depression scales. Anxiety strongly negatively predicted
the function; to a lesser extent, Schizophrenia also negatively predicted the function.
The structure correlations (Table 6) demonstrated that Borderline and Antisocial evinced
the highest correlations with the function, followed by Mania, Schizophrenia, and
Depression. Group centroids were .92 for stimulant users and -.35 for other drug users.
Therefore, the function characterizes stimulant users as elevated on personality disorders
whose primary traits include impulsivity, irritability, and affective instability, and to a
lesser extent, mood disturbance distinguished stimulant users from other drug users. The
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role of the Schizophrenia scale is somewhat unclear, as it evinces a moderate correlation
with the function but demonstrates a small but negative impact.
Table 6

A Priori Discriminant Analysis Results, PAI
Dependent Variables
Anxiety
Depression
Mania
Schizophrenia
Borderline
Antisocial

Structure Matrix
(Correlations)
.24
.41
.46
.44
.81
.77

Standardized Discriminant
Function Coefficients
-0.72
0.30
0.20
-0.24
1.04
0.30

With regards to the heuristic hypotheses, the stimulant use dichotomy was again
entered as the independent variable, with the remaining seven scales ofthe PAl entered
as dependent variables into a MANOVA. Covariance homogeneity was supported by
Box's test, M = 36.11, F(28, 11929) = 1.17, p = .245. Stimulant use explained a
significant portion of the variance in the multivariate model, Pillai 's Trace = .1 6, F(7,
105) = 2.90, p = .008, partial r/ = .16. Univariate analyses indicated that stimulant use
was associated with significantly higher scores on Paranoid, F(l , 111) = 10. 76, p = .001 ,
and Suicide Ideation scales, F(l, 111) = 11.52, p < .001, compared to other drug use.
Drug Problems, F(1, 111) = 5.08,p = .026, and Aggression, F(1, 111) = 10.10, p = .002,
approached significance but did not meet the p < .001 level. The Anxiety Related
Disorders scale, F(l , 111) = 2.27,p = .135, and the Somatization scale, F(l , 111) = 1.62,
p = .205, did not differentiate between stimulant use and other drug use. Means, standard

deviations, and effect sizes are presented in Table 7.
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Table 7
Heuristic Univariate Analyses, PAI

Dependent Variables

Somatic Concerns
Anxiety Related Disorders
Paranoia***
Alcohol Concerns
Drug Concerns*
Aggression**
Suicide Ideation***

Stimulant Use
(N=31)
Mean/SD
59.97/13.82
65.19/13.73
60.68/14.71
81.10/21.50
83.61 /23.41
55.32/13.31
62.26/ 17.81

Other Drug Use (N =
82)
Mean/SD
56.71 /11.45
60.98/13.11
52.32/10.96
78.50/22.82
72.56/23.19
47.41111.27
52.51 / 11.69

Eta Squared

.01
.02
.09
.00
.04
.08
.09

Note: •p < .05, .. p < .01, ...P < .001

DDA was used to further separate the stimulant group from the other drug use,
using the six remaining P AI scales. Log determinants were approximately equal (Group
1: 35 .92, Group 2: 36.96, Error: 36.53), providing additional evidence for the
homogeneity of covariance matrices. One function was extracted from the data, A = .84,
iCdf7) = 19.01, p

=

.008. The canonical r 2 was equal to .16, indicating that the

discriminant function accounted for 16.2% of the variance. Standardized canonical
discriminant function coefficients (Table 8) indicated that the function was primarily and
equally predicted by the Suicide Ideation and Paranoid scales, and to a lesser extent, the
Drug and Aggression scales. Anxiety Related Disorders slightly negatively impacted the
function. The structure correlations (Table 8) demonstrated that Suicide Ideation,
Paranoia, and Aggression had the highest correlations with the function, followed by
Drug Use. Group centroids were .71 for stimulant users and -.27 for other drug users.
Stimulant users are thus characterized primarily in terms of their suicidality, paranoia,
and aggression, but may also be distinguished by drug use.
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Table 8
Heuristic Discriminant Analysis Results, PAI
Dependent Variables
Somatic Concerns
Anxiety Related Disorders
Paranoia
Alcohol Concerns
Drug Concerns
Aggression
Suicide Ideation

Structure Matrix
(Correlations)
.28
.33
.71
.12
.49
.69
.73

Standardized Discriminant
Function Coefficients
-0.05
-0.22
0.49
0.12
0.27
0.28
0.55

Results, MCMI-III
Per the a priori hypotheses, the stimulant use dichotomy was entered as the
independent variable, and the Anxiety, Bipolar: Manic, Dysthymia, Thought Disorder,
Major Depression, Borderline, and Antisocial scales of the MCMI-III were entered as
dependent variables into a MANOVA. Covariance homogeneity was not supported by
Box's test, M= 83.52, F(28, 14152) = 2.72, p < .001; in conjunction with evidence of
normality violations and unequal group sizes, these results should be interpreted with
caution. The multivariate model explained a significant portion of the variance in
stimulant use, Pillai 's Trace= 0.943, F(7, 103) = 3.31, p = .003, partial r/ = .18.
Univariate analyses indicated that stimulant use was associated with significantly higher
scores on Borderline, F(1, 109) = 20.62, p < .001, and Antisocial scales, F( 1, 109) =
14.26,p < .001, compared to other drug use. Again, Bipolar: Manic, F(1, 109) = 9.76,p =
.002, Dysthymia, F(1, 109) = 4.26,p = .041, and Thought Disorder, F(1, 109) = 8.09,p
=

.005, approached significance. The Anxiety scale was not interpreted due to violations

in equality of variance. The Major Depression scale did not differentiate between
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stimulant use and other drug use, F(l, 109) = 2.21 , p = .140. Means, standard deviations,
and effect sizes are presented in Table 9 ..
Table 9
A Priori Univariate Analy~es, MCMI-111
Dependent Variables

Anxiety
Bipolar: Manic**
Dysthymia*
Thought Disorder**
Major Depression
Antisocial***
Borderline***

Stimulant Use
(N=33)
Mean/SD
83.12/12.40
67.09/22.76
73.67/23.32
66.03/12.71
64.88/33.06
79.91/15.65
77.45/15.96

Other Drug Use
(N = 78)
Mean/SD
71.15/29.31
50.76/26.12
62.40/27.43
52.90/25.15
54.60/33.38
63.95/22.01
56.41124.48

Eta Squared

.04
.08
.03
.07
.02
.12
.16

Note: *p < .05, **p < .01 , ***p < .001

DDA was used to determine the ability of the seven personality and
psychopathology scales to separate stimulant use from other drug use. Log determinants
showed some variability but were not grossly different (Group 1: 41.53, Group 2: 36.68,
Error: 40.87), providing some evidence for the homogeneity of covariance matrices;
however, caution should still be employed. One function was extracted from the data, A
= .82,

i (df7) = 21.39,p = .003.

The canonical r 2 was equal to .18, indicating that the

discriminant function accounted for 18% of the variance. Standardized canonical
discriminant function coefficients (Table 10) indicated that the function was almost
entirely driven by the Borderline scale; the Major Depression scale negatively predicted
the function. The structure correlations (Table 10) demonstrated that Borderline and
Antisocial evinced the highest correlations with the function, followed by the Bipolar:
Manic and Thought Disturbance scale. Given the violations found with this model,
structure correlations were not interpreted below .5, in order to minimize error
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(Dalgleish, 1994; Finch, 2009). Group centroids were .72 for stimulant users and -.31 for
other drug users. With the exception of the contribution ofthe Major Depression scale,
the results of the DDA using the MCMI-III scales were entirely consistent with the
results ofthe DDA using the PAl scales above. Therefore, despite violations the function
again distinguishes stimulant users as elevated on personality disorders whose criteria
include impulsivity, irritability, and affective instability; to a lesser extent, mania, thought
disorganization, and confusion distinguished stimulant users from other drug users.
Table 10

A Priori Discriminant Analysis Results, MCM1-111
Dependent Variables
Anxiety
Bipolar: Manic
Dysthymia
Thought Disorder
Major Depression
Antisocial
Borderline

Structure Matrix
(Correlations)
.46

.63
.42

.58
.30
.76
.92

Standardized Discriminant
Function Coefficients
-0.07
0.08
0.02
0.18
-0.36
0.29
0.82

With regards to the final heuristic hypothesis, the stimulant use dichotomy was
entered as the independent variable, with the remaining 17 scales of the P AI entered as
dependent variables into a MANOVA. It should be noted that this MANOVA is
underpowered and corresponding discriminant analysis results may not be stable due to
small sample size. Covariance homogeneity was supported by Box's test, M

=

231 .57,

F(153, 10000) = 1.57, p = .091. Stimulant use explained a significant portion ofthe
variance in the multivariate model, Pillai 's Trace= .317, F(17, 92) = 2.52,p = .003,

partialrt2 = .32. Univariate analyses indicated that stimulant use was associated with
significantly higher scores on Sadistic, Negativistic, and Drug Dependence, compared to
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other drug users. Conversely, other drug users score significantly higher on the
Compulsivity scale, relative to stimulant users. Means, standard deviations, F-values, and
effect sizes are presented in Table 11.
Table 11

Unplanned Univariate Analyses, MCMI-111
Dependent Variables

Schizoid
Avoidant
Depressive
Dependent
Histrionic
Narcissistic
Sadistic***
Compulsive***
Negativistic***
Masochistic*
Schizotypal*
Paranoid*
Somatoform
Alcohol Dependence*
Drug Dependence***
Posttraumatic
Stress**
Delusional Disorder*

Stimulant Use
(N=30)
Mean/SD
54.47/22.04
59.60/26.67
67.33/26.45
78.70/ 19.03
49.20/27.51
54.27/23 .64
65.30/ 12.31
27.50/ 16.99
67.33/15.02
71.87/ 17.85
55.37/22.54
53.40/24.57
50.80/24.42
86.33/ 15.55
84.30/20.18
66.20/11 .66

Other Drug Use
(N = 80)
Mean/SD
45.60/27.76
52.73/31.78
62.23/27.11
69.04/26.59
49.71/23.00
49.65/ 19.30
52.63/ 19.32
50.53/20.80
47.98/24.89
58.95/28.77
44.25/27.26
39.75/27.35
46.63/25.78
75.16/27.85
63.41/30.24
52.49/25.96

F

Eta
Squared

2.47
1.11
0.79
3.32
0.01
1.10
11.17
29.35
15.92
5.27
3.97
5.73
0.59
4.62
12.23
7.75

.02
.01
.01
.03
.00
.01
.09
.21
.13
.05
.04
.05
.01
.04
.10
.07

42.03/24.44

28.84/26.34

5.69

.05

Note: •p < .05, ••p < .01, u•p < .001 ; df are I & 108
Bolding denotes an inability to interpret due to violations to equality of variance

DDA was used to further separate the stimulant group from other drug use using
the 17 remaining PAI scales. Log determinants were not equal (Group 1: 96.91, Group 2:
87.65, Error: 96.56), providing evidence against the homogeneity of covariance matrices.
One function was extracted from the data, A = .68,

i (df 17) = 37.99,p = .002. The

canonical r 2 was equal to .32, indicating that the discriminant function accounted for 32%
of the variance.
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Due to violations in assumptions, .50 was used as an interpretive cut-off to
minimize error (Dalgleish, 1994). Standardized canonical discriminant function
coefficients (Table 12) indicated that the function was primarily predicted by the
Histrionic, Negativistic, Avoidant, and Posttraumatic Stress scales. The Compulsive scale
was a negative predictor of the function. The structure correlations (Table 12)
demonstrated that the function was primarily positively correlated with Negativistic scale
and negatively correlated with the Compulsive scale. There was some disagreement
between the standardized coefficients and the structure correlations (e.g., Histrionic
scale). Therefore, the structure correlations will be the focus of interpretation, as there is
some evidence that these correlations evince increased stability in small sample sizes
(Stevens, 2002). Group centroids were 1.10 for stimulant users and -.41 for other drug
users. Therefore, the function characterizes stimulant users in terms of their passiveaggression and lack of compulsivity.
Table 12
Heuristic Discriminant Analysis Results, MCM1-111

Dependent Variables
Schizoid
Avoidant
Depressive
Dependent
Histrionic
Narcissistic
Sadistic
Compulsive
Negativistic
Masochistic
Schizo typal
Paranoid
Somatoform

Structure Matrix
(Correlations)
.22
.15
.13
.26
-.01
.15
.47
-.77
.56
.32
.28
.33
.11

Standardized Discriminant
Function Coefficients
0.35
0.54
-0.76
-0.07
0.62
-0.00
-0.21
-0.83
0.55
0.13
-0.11
-0.15
-0.33
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Table 12 (continued).
Dependent Variables
Alcohol Dependence
Drug Dependence
Posttraumatic Stress
Delusional Disorder

Structure Matrix
(Correlations)
.30
.49
.39
.34

Standardized Discriminant
Function Coefficients
-0.04
-0.05
0.52
0.09
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CHAPTER IV
SUMMARY
Discussion
Consistent with previous literature, women who used stimulants were separated
from women who used all other forms of drugs on the basis of a relatively cohesive
pattern of symptomatology. First and foremost, scales measuring traits linked with
borderline personality disorder consistently and overwhelming separated stimulant users
from other drug users. Additionally, scales measuring features of antisocial personality
disorder consistently discriminated between stimulant users and other drug users, though
these scales demonstrated less of an impact. These results are consistent with overlap
between the diagnostic criteria of these two disorders, as they both feature difficulties
with impulsivity, aggression, and emotion regulation (APA, 2000). Results are also
consistent with findings of neuroimaging studies, which suggest that individuals addicted
to stimulant drugs experience impairment in cognitive inhibition, emotion regulation, and
impulsivity (review: Li & Sinha, 2008). The temporal precedence of stimulant use and
these symptoms are still under investigation; however endophenotypic markers in
humans (Ersche, Williams, Robbins & Bullmore, 2013) and trait studies in animals
(Badiani et al., 2011) suggest that impairments precede stimulant use, but are exacerbated
upon initiation of drug use.
Secondary to these personality types, stimulant users appeared to be separated
from other drug users by mood disturbance. Both the PAI and MCMI-III separated
stimulant users on the basis of manic symptoms. It was beyond the scope of this study to
elucidate whether women experienced true symptoms of mania, or presented with manic-
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like symptoms secondary to their stimulant use. Considering the rather paradoxical
research investigating the use of prescription stimulants as a treatment for bipolar
disorder (Pagano et al., 2008; Wingo & Ghaemi, 2008), it may be possible that women
with mania were attempting to self-medicate their symptoms. It is equally possible that
the measures utilized in the study had difficulty differentiating between the two
presentations, given the overlap in symptoms. When using the MCMI-III, the average
individual using stimulants reached the clinical range on the Bipolar: Manic scale;
however, on the PAI, the average stimulant user was in the normative range on the Mania
scale. Therefore, it may be that the PAl demonstrated better clinical utility in separating
true symptoms of mania from those of stimulant use.
There was some evidence that depressive symptomatology also separated
stimulant use from other drug use, although there was some conflict between measures.
Results from planned analyses using the P AI indicated that depression was moderately
correlated with stimulant use and had a small impact on predicting stimulant use, whereas
results from the MCMI-III did not. Given the numerous violations of assumptions in the
MCMI-III data, the results ofthe PAl should be accorded more weight. Additionally, the
inclusion of both Dysthymia and Major Depression scales into the planned analysis using
the MCMI-III may have diluted the results at the multivariate level and masked group
differences. Therefore, consistent with previous research, women using stimulants may
suffer from higher rates of depression and overall mood disturbance, but these clinical
syndromes may play less of a role than severe personality pathology.
With regards to thought disturbance or psychosis, results suggested that stimulant
users may experience slightly higher levels of symptomatology than other drug users.
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However, scales measuring these constructs were correlated with functions measuring
stimulant use, but either did not differentiate or made a small negative impact on
functions separating stimulant use from other drug use. Thus, it may be that individuals
experiencing thought disturbance are less likely to seek stimulants, particularly as the
literature suggests that stimulant use may exacerbate positive symptoms of psychosis
(reviews: reviews: Dawe et al., 2009; Shoptaw et al., 2009). Conversely, women who
chronically use stimulants may find that they temporarily experience psychotic symptoms
as a result of their use, but may not have insight into the relationship between stimulant
use and psychosis. The average scores of stimulant users indicated that these women may
experience "brief reactive psychosis" (Millon et al., 2009, p. 24) and may occasionally
display inappropriate affect, disorganized thinking, and social isolation.
Exploratory analyses indicated that stimulant users were separated principally by
elevations in scales measuring symptoms of suicidal ideation, paranoia, and aggression,
and to a lesser extent, drug use. Additionally, stimulant use was defined by a passiveaggressive personality style, which was described as "vacillation between deference and
defiance, between obedience and aggression," (Millon et al., p.l8). Ofthese scales, only
aggression was below the clinical range for experiencing significant symptom related
distress or consequences. On the surface, these may appear to be a cluster of unrelated
symptoms. However, each of these scales measure distinct diagnostic or associated
features of borderline personality disorder (APA, 2000), giving additional weight to the
premise that treatment-seeking women using stimulants may be primarily defined by
borderline personality disorder. Specifically, these scales capture the following
symptoms, as defined by AP A (2000): "a pattern of ... interpersonal relationships
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characterized by alternating between extremes of idealization and devaluation,"
"impulsivity," "recurrent suicidal behavior, gestures, or threats," "affective instability,"
"inappropriate, intense anger or difficulty controlling anger," "transient, stress-related
paranoid ideation," (p. 710) and the associated feature of"psychotic-like
symptoms . .. during times of stress," (p. 708). Stimulant use may simultaneously
aggravate symptoms of borderline personality disorder (e.g., impulsivity, aggression) and
serve as a coping mechanism for mood dysregulation and affective disturbance.
These findings are largely consistent with the results of Chen et al. (20 11 ), in that
mood disorder, psychotic symptoms, borderline personality disorder, and antisocial
personality disorder symptoms are highly problematic among women who use stimulant
drugs. Furthermore, results are consistent with Feske et al. (2006), who reported that
borderline personality disorder was a significant predictor for multiple categories of
substance use, including poly-substance use. Within our sample, 97.3% of women using
stimulants also used at least one other substance, compared to 44.8% of women using
other types of substances.
Consistent with previous research, our sample of women presenting with
stimulant use was saturated with comorbid eating disorder diagnoses (59.5%), compared
to women presenting with other substance use disorders (25.3%). With regard to eating
disordered symptomatology, women who used stimulants were separated from other drug
users primarily by Emotion Dysregulation, a psychological scale posited to be associated
with eating disorders, and Drive for Thinness. Although Emotion Dysregulation had a
marginally higher correlation with the function defining stimulant use, Drive for Thinness
overwhelmingly predicted stimulant use. Therefore, consistent with previous research,
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stimulant use was associated with caloric constraint, extreme dieting, and a yearning for
thinness, above and beyond other types of drug use. Additionally, it may be that the
extreme dieting enacted by stimulant users interacted with their mood to exacerbate
difficulties with regulating emotions. Previous research indicates that starvation is
associated with symptoms mimicking mood disturbance (Casper, 1998; Pearlstein, 2002).
Given the physiological properties associated with stimulant use (e.g., decreased
hunger, euphoria), it is possible that stimulant use served in a functional nature, in that it
improved the individual's mood and ability to diet. Although this study was not causal in
nature, the thin ideal espoused by women who used stimulants suggests that their
stimulant use may have developed as a result of their motivation to lose weight,
consistent with hypotheses in prior research (Baker, Mitchell, Neale, & Kendler, 2010;
Holderness et al. , 1994). Further research is needed to clarify the temporal precedence of
stimulant use in women with eating disordered symptomatology.
Contrary to a priori hypotheses, stimulant users were not separated from other
drug users by anxiety or anxiety related disorders. Stimulant users still appear to have
difficulty with anxiety, as their average scores on anxiety and anxiety-related scales were
suggestive of clinically significant symptoms. Given the link to borderline personality
disorder, stimulant users may experience anxiety symptoms as one of numerous, intense
mood states, thus explaining the elevations in scores. As women who used stimulants
were also poly-substance users, they may seek different substances to alleviate particular
mood states (e.g., stimulants for dysphoria, sedatives for anxiety). However, women
presenting with pure anxiety disorders may seek other types of drugs, as the consistent
heightened physiological arousal associated with anxiety may cause aversive reactions to
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stimulants. Additionally, anxiety symptoms may partially result from stimulant use. For
example, multiple animal studies have demonstrated elevations in anxiety in rats
administered cocaine; studies suggested that consistent stimulant use resulted in
anxiogenic effects (Erb, Kayyali, & Romero, 2006; Mantsch et al., 2008; Muller et al.,
2008).
Finally, stimulant use was not separated from other drug use by purging
behaviors, contrary to the a priori hypothesis. Given the extensive evidence in the
literature for this relationship, the lack of findings in this study was likely related to
limitations in instrumentation. This study did not have a pure measure of purging, but
rather, a scale measuring the combination ofbingeing and purging, as well as associated
features such as drug use (i.e., the Bulimia scale). Therefore, many items on the scale
may not have been relevant to the purging construct and may have masked important
differences in purging behaviors between stimulant users and other drug users. The
results of this study should not be interpreted as evidence against the stimulant use and
purging relationship, particularly as constructs associated with purging were significant
in the stimulant use profile.
Implications for Treatment
Given these findings, it is important to note that women seeking treatment for
stimulant use disorders may present with a number of serious psychological problems. In
such women, stimulant use may be secondary to longstanding personality pathology (i.e.,
borderline personality disorder) and eating disorder symptomatology. It will be necessary
to carefully screen clients presenting for stimulant use and to triage their psychological
and medical problems, focusing on those which may be life threatening (e.g., suicidality,
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starvation associated with anorexia). If these features are present, the necessity for
hospitalization should be carefully evaluated. Subsequently, a treatment plan should be
developed, with the knowledge that an addiction focused treatment plan may not be
effective in isolation, as it may not consider or treat the primary problems motivating
stimulant use.
Given the findings of the current study, stimulant users may benefit from
Dialectical Behavioral Therapy (DBT) in an effort to treat the symptomatology
associated with borderline personality disorder (Linehan et al., 2006) and accompanying
substance use (van den Bosch, Verheul, Schippers, & van den Brink, 2002); there is
limited evidence regarding its effectiveness in treating eating disorders (e.g., Safer,
Robinson, & Jo, 2010), although skills learned may present some benefit to women with
eating disorders. DBT focuses on skill acquisition in the areas of distress tolerance,
emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 1993).
Women presenting with comorbid stimulant use and antisocial personality
disorder may benefit from motivational enhancement therapy (Miller, Zweben,
DiClemente, & Rychtrik, 1992), to reduce their substance use and aid in treatment
attendance and motivation. However, if stimulant users present with primarily eating
disorder symptomatology, cognitive behavioral approaches (e.g., cognitive behavioral
therapy for eating disorders; Fairburn, 2008) should be considered in order to target the
underlying desire for thinness and weight control. It is important to note that the results of
the current study are isolated to women and these treatment implications may not be
generalizable to men who seek treatment for stimulant use.
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Limitations of the Current Study
The current study had several limitations. Due to time constraints, it was not
possible to collect more than 124 participants, so power may have been a limitation,
particularly in the exploratory analyses which utilized a large number of scales.
Additionally, several scales within the data demonstrated a non-normal distribution,
which could not be corrected due to inconsistencies in the directionality of the skewness
and kurtosis. Although multivariate tests for normality were within an acceptable range,
the lack of equality between cell sizes, in conjunction with the lack of univariate
normality in a number of the scales, indicate that these results should be interpreted with
caution as the combination of these two violations can result in an overly liberal F
statistic (Meyers et al., 2006).
Additionally, all of the measures utilized in this study were self-reported, which
introduced the opportunity for bias via impression management and misunderstanding.
Attempts were made to control for bias where possible (e.g., use of validity scales,
presence of the patient's mental health clinician). However, the study would have
benefited from collateral sources of reporting, clinician based measures, or behavioral
monitoring, such as ecological momentary based assessment.
The current study may also have been hindered by uncontrolled, third variables.
As the study examined only the presence or absence of stimulant use, women in both
groups may have used a multitude of other drugs. This approach to the data increased
confidence in the external validity of the results, as many individuals seeking treatment
for alcohol and drug use present with poly-drug use, a premise which was supported by
our data. However, this approach failed to account for the possibility that a different drug
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may have been responsible for the group differences or masked true differences.
Additionally, other, unmeasured constructs besides substance use may have accounted for
the group differences in personality and psychopathology, The overlap in findings
between the current study and the literature, however, do not provide evidence of a third
variable problem.
Finally, the generalizability of the results are somewhat limited in this study,
given the lack of randomization, use of an accessible population, lack of anorexia
nervosa, restricting subtype diagnoses, and the complete lack of male participants. As the
entire sample is from a treatment center in the southeastern United States, the sample
may be unrepresentative of the general population or may be heterogeneous in some way.
Furthermore, it was beyond the resources of this study to collect a sample of pure
stimulant users. Although the current study offers much in the way of ecological validity,
results of stimulant users who are also poly-drug users may not generalize to pure
stimulant users.
Future Directions
Future studies should investigate potential gender differences in the clinical
presentation of individuals with stimulant use disorders, as this study used only women
participants. Furthermore, future studies should attempt to include a full range of eating
disorder diagnoses (e.g., ANr), as well as both pure and poly-drug stimulant users, to
more fully tease apart differences in clinical presentation associated with various patterns
of comorbidity. Additionally, the results of this study should be replicated in a larger
study, as certain exploratory analyses lacked the power to adequately rule out type I and
II error. Furthermore, although numerous studies hypothesized the causal relationship
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between stimulant use, emotion regulation, and eating disorder symptomatology, the
literature would benefit from a well-controlled longitudinal study to examine the nature
of these relationships.
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